ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

This article originally appeared here.
Share this content:
ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma
ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

MONDAY, Dec. 11, 2017 (HealthDay News) -- For patients with advanced-stage Hodgkin's lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), according to a study published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in Atlanta.

Joseph M. Connors, M.D., from the British Columbia Cancer Agency in Vancouver, Canada, and colleagues conducted a phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma. A total of 664 patients were assigned to receive A+AVD and 670 were assigned to receive ABVD.

The researchers found that the two-year progression-free survival rates were 82.1 and 77.2 percent in the A+AVD and ABVD groups at a median follow-up of 24.9 months (hazard ratio for an event of progression, death, or modified progression, 0.77; 95 percent confidence interval, 0.60 to 0.98; P = 0.03). There were 28 and 39 deaths with A+AVD and ABVD (hazard ratio for interim overall survival, 0.72; 95 percent confidence interval, 0.44 to 1.17; P = 0.19). There was a trend in favor of A+AVD for all secondary efficacy end points.

"A+AVD had superior efficacy to ABVD in the treatment of patients with advanced-stage Hodgkin's lymphoma, with a 4.9 percentage-point lower combined risk of progression, death, or noncomplete response and of subsequent anticancer therapy at two years," the authors write.

The study was funded by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals, and Seattle Genetics.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

Proinflammatory Diet Linked to Increased Colorectal Cancer Risk

Proinflammatory Diet Linked to Increased Colorectal Cancer Risk

Higher empirical dietary inflammatory pattern score linked to increased risk of CRC for men and women

Longer Duration of Post-Op Opioid Use Associated With Misuse

Longer Duration of Post-Op Opioid Use Associated With ...

Higher dose, shorter duration Rx may minimize risk of longer term misuse, authors say

Alcohol Induced DNA Repair Genes Prognostic in Gastric Cancer

Alcohol Induced DNA Repair Genes Prognostic in Gastric ...

BRF1, BRCA1/2, MPO induced by alcohol have prognostic value for patients with gastric cancer

is free, fast, and customized just for you!

Already a member?

Sign In Now »